Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Clinical pharmacology and therapeutics - 1 Jul 2006

Borges Silvana, Desta Zeruesenay, Li Lang, Skaar Todd C, Ward Bryan A, Nguyen Anne, Jin Yan, Storniolo Anna Maria, Nikoloff D Michele, Wu Lin, Hillman Grant, Hayes Daniel F, Stearns Vered, Flockhart David A

Abstract excerpt

BACKGROUND AND OBJECTIVES: N-Desmethyltamoxifen (NDM), a major primary metabolite of tamoxifen, is hydroxylated by cytochrome P450 (CYP) 2D6 to yield endoxifen. Because of its high antiestrogenic potency, endoxifen may play an important role in the clinical activity of tamoxifen. We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Hormonal

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Genotype

Share to Tamoxifen

Source

Identifiers

PMID: 16815318
DOI: 10.1016/j.clpt.2006.03.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.PMID 16815318Read ↗

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.Semantic proximity Read ↗

Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency.Semantic proximity Read ↗

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.Semantic proximity Read ↗

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with TamoxifenSemantic proximity Read ↗

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.Semantic proximity Read ↗

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio.Semantic proximity Read ↗

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.Semantic proximity Read ↗

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast CancerSemantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balanceSemantic proximity Read ↗

Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.Semantic proximity Read ↗

Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.Semantic proximity Read ↗

CYP2D6 polymorphisms and the impact on tamoxifen therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.